Pilot Study of Internet-Delivered Psychological Treatment for Cancer Survivors (IN-FACT-0)

Pilot Study of Internet-Delivered Psychological Treatment for Cancer Survivors With Clinically Significant Psychiatric Symptoms

Negative psychological effects of cancer are common, but cancer survivors are rarely offered structured psychological treatment. Internet-delivered treatments have shown some promise, but specific treatment components have not been empirically evaluated which means that it is not clear which therapies that should be prioritized. In this factorial pilot study, 48 cancer survivors with psychiatric symptoms are enrolled in variations on a 10-week therapist-guided online psychological treatment intended to address common negative psychological long-term effects of cancer. The aim of this study is to assess the feasibility of the study design and online treatment format. Key feasibility outcomes include interest in the study, patient-reported credibility of the intervention, adherence to the treatment protocol, satisfaction with the treatment, acceptability of the measurement strategy, missing data rates, adverse events, and preliminary efficacy on anxiety, depression, the fear of recurrence, and health-related quality of life.

Study Overview

• Status: Completed
• Conditions: Depression; Anxiety; Cancer Survivors
• Intervention / Treatment: Behavioral: Support and information; Behavioral: Behavioral activation; Behavioral: Systematic exposure with mindfulness training; Behavioral: Promotion of health behaviors

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden
    • Karolinska Institutet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Cancer survivor at least 0.5 years after main therapy. Survivor of breast cancer (n=24), testicular cancer (n=12), or thyroid cancer (n=12).
• Clinically significant anxiety or depression (Patient Health Questionnaire 9 [PHQ-9]≥10, or Generalized Anxiety Disorder 7 [GAD-7]≥8, or 9-item Fear of Cancer Recurrence Inventory [FCRI-9]≥16)
• At least 18 years old
• Resident of Sweden (listed and de facto)
• Sufficient technical knowledge and knowledge of the Swedish language to take part in a text-based online treatment
• Continuous access to an electronic device that can be used to access the study web platform

Exclusion Criteria:

• Recurrent thoughts of suicide, as based on clinical judgement aided by the structured interview and the self-report version of the Montgomery-Åsberg Depression Rating Scale (MADRS-S) item 9
• Severe medical condition (e.g., very poor prognosis, stage IV cancer), severe psychiatric disorder (e.g., psychotic disorder, bipolar disorder, or severely debilitating substance use disorder, severe depression), or medical treatment (e.g., chemotherapy, immunotherapy, radiotherapy) that makes the treatment unfeasible
• Other ongoing psychological treatment
• Continuous psychotropic medication not stable for the past 4 weeks, or not expected to remain stable during the treatment period
• Planned absence for more than one week of the intended treatment period
• No complete the pre-treatment assessment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Single

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Internet-delivered psychological treatment, arm #1; Support and information + Behavioral activation	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Behavioral activation; Behavioral activation with existential themes and emphasis on values and relationships.
Experimental: Internet-delivered psychological treatment, arm #2; Support and information + Systematic exposure with mindfulness training	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Systematic exposure with mindfulness training; Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
Experimental: Internet-delivered psychological treatment, arm #3; Support and information + Promotion of health behaviors	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Promotion of health behaviors; An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
Experimental: Internet-delivered psychological treatment, arm #4; Support and information + Behavioral activation + Systematic exposure with mindfulness training	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Behavioral activation; Behavioral activation with existential themes and emphasis on values and relationships.; Behavioral: Systematic exposure with mindfulness training; Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
Experimental: Internet-delivered psychological treatment, arm #5; Support and information + Behavioral activation + Promotion of health behaviors	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Behavioral activation; Behavioral activation with existential themes and emphasis on values and relationships.; Behavioral: Promotion of health behaviors; An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
Experimental: Internet-delivered psychological treatment, arm #6; Support and information + Systematic exposure with mindfulness training + Promotion of health behaviors	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Systematic exposure with mindfulness training; Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.; Behavioral: Promotion of health behaviors; An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
Experimental: Internet-delivered psychological treatment, arm #7; Support and information + Behavioral activation + Systematic exposure with mindfulness training + Promotion of health behaviors	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.; Behavioral: Behavioral activation; Behavioral activation with existential themes and emphasis on values and relationships.; Behavioral: Systematic exposure with mindfulness training; Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.; Behavioral: Promotion of health behaviors; An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
Experimental: Internet-delivered psychological treatment, arm #8; Support and information	Behavioral: Support and information; Emotional and technical support. Information about the long-term effects of cancer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility 1: Feasibility of the randomized factorial design	A key feasibility outcome of this pilot study is the overall experience of study administrators and therapists tasked with the assignment and delivery of treatment variants in accordance with the randomized factorial design. After the main phase, all study administrators and therapists will be asked to rate the feasibility of the planned study design from 0 ("not feasible at all") to 10 ("fully feasible"), which will reported as a mean (SD) and median.	Post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 2: Credibility of the treatment as perceived by patients	Credibility/Expectancy scale (C/E scale). Theoretical range: 0-50, where a higher score indicates higher credibility/expectancy.	Week 2 of treatment
Feasibility 3: Adherence to the treatment protocol #1	Number of modules initiated, as registered by the clinician.	Over the 10-week treatment period, with registration at the post-treatment assessment (immediately after treatment).
Feasibility 4: Adherence to the treatment protocol #2	Number of completed exercises, as based on a short weekly questionnaire tailored to suit each treatment arm, with corresponding questions about the number of days devoted to exposure exercises, days devoted to activity planning, and days devoted to the promotion of health behaviors.	Each week from the beginning of treatment to the post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 5: Acceptability of the online measurement strategy #1	Number of measurements completed at each measurement point after the pre-treatment assessment. Preregistered target: at least 70% non-missing at the post-treatment and follow-up assessments.	Each week from the Each week from the beginning of treatment to the follow-up assessment (3 months after treatment)
Feasibility 6: Acceptability of the online measurement strategy #2	Perceived strain caused by the measurement strategy. Preregistered target: at least 75% with a rating below 7 from 0 ("not at all stressful/distressing") to 10 ("extremely stressful/distressing").	Post-treatment assessment (within 45 days after treatment)
Feasibility 7: Patients' satisfaction with the treatment #1	The 8-item Client Satisfaction Questionnaire (CSQ-8). Theoretical range: 8-32, where a higher score indicates higher satisfaction.	Post-treatment assessment (within 45 days after treatment)
Feasibility 8: Patients' satisfaction with the treatment #2	Likert items pertaining to satisfaction with components.	Post-treatment assessment (within 45 days after treatment)
Feasibility 9: Rate of adverse events and negative experiences #1	Questionnaire used in previous clinical trials (e.g., ClinicalTrials.gov: NCT04511286)	Post-treatment assessment (within 45 days after treatment)
Feasibility 10: Rate of adverse events and negative experiences #2	20-item Negative Effects Questionnaire (NEQ-20). This will be reported as the proportion of endorsed items in the following subdomains: increase in symptoms, perceived insufficient quality of treatment, dependency, stigma, and hopelessness.	Post-treatment assessment (within 45 days after treatment)
Feasibility 11: Preliminary efficacy in terms of within-group average change in general anxiety	General Anxiety Disorder 7 (GAD-7, theoretical range: 0-21, where a higher score indicates more general anxiety)	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 12: Preliminary efficacy in terms of within-group average change in depressive symptoms	Patient Health Questionnaire 9 (PHQ-9, theoretical range: 0-27, where a higher score indicates more symptoms of depression)	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 13: Preliminary efficacy in terms of within-group improvement in the fear of cancer recurrence	9-item Fear of Cancer Recurrence Inventory (FCRI-9, theoretical range: 0-36, where a higher score indicates a more pronounced fear of cancer recurrence)	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 14: Preliminary efficacy in terms of within-group improvement in health-related quality of life	36-item Short Form Health Survey (SF-36, scored as a Mental Health Component Score and a Physical Health Component Score according to standard norms, both with a theoretical range of 0-100, where a higher score indicates a higher health-related quality of life)	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Relationship with the therapist (therapeutic alliance)	Working Alliance Inventory (WAI, theoretical range: 6-42, where a higher score indicates a stronger therapeutic alliance)	Week 2 of treatment
Symptom domains surveyed primarily to assess the feasibility of the measurement method: Health anxiety.	14-item Health Anxiety Inventory (HAI-14, theoretical range: 0-42, where a higher score indicates more health anxiety).	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days). Secondary analysis: from pre-treatment up to follow-up 3 months after treatment.
Symptom domains surveyed primarily to assess the feasibility of the measurement method: Somatic symptom burden.	Somatic Symptom Scale 8 (SSS-8, theoretical range: 0-32, where a higher score indicates a higher somatic symptom burden). Exploratory secondary analyses will be based on individual items, each scored 0-4.	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days). Secondary analysis: from pre-treatment up to follow-up 3 months after treatment.
Symptom domains surveyed primarily to assess the feasibility of the measurement method: Disability.	12-item WHO Disability Assessment Schedule 2.0 (WD2-12, theoretical range: 0-100, where a higher score indicates more disability).	Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days). Secondary analysis: from pre-treatment up to follow-up 3 months after treatment.
Process and target variables surveyed primarily to assess the feasibility of the measurement method: Behavioral activation	3-item Behavioral Activation for Depression Scale - Activation (BADS-AC-3, theoretical range: 0-18, where a higher score indicates a higher level of behavioral activation).	Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 45 days), and at follow-up 3 months after treatment (completed within 45 days).
Process and target variables surveyed primarily to assess the feasibility of the measurement method: Symptom preoccupation	Symptom Preoccupation Scale (preliminary scale). A higher score indicates higher degree of preoccupation with symptoms. This is to be regarded as an an item pool, and the scale is is under development, which means that the total range cannot be preregistered.	Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 45 days), and at follow-up 3 months after treatment (completed within 45 days).
Process and target variables surveyed primarily to assess the feasibility of the measurement method: Physical activity	Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ, theoretical range 0-99, where a higher score indicates a higher level of physical activity). If necessary for statistical modeling, the GSLTPAQ will be dichotomized to indicate active (≥24) vs. insufficiently active (<24).	Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 45 days), and at follow-up 3 months after treatment (completed within 45 days).
Process and target variables surveyed primarily to assess the feasibility of the measurement method: Health-related self-efficacy.	Based loosely on the Arthritis Self-efficacy Scale. Theoretical range of 0-60, where a higher score indicates a higher level of general health-related self-efficacy.	Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 45 days), and at follow-up 3 months after treatment (completed within 45 days).
Screening only: Alcohol use	Alcohol Use Disorders Identification Test (AUDIT, theoretical range: 0-40, where a higher score indicates more problematic alcohol use).	At screening
Screening only: Substance use	Drug Use Disorders Identification Test (DUDIT, theoretical range: 0-44, where a higher score indicates more problematic substance use).	At screening
Screening only: General distress	Hospital Anxiety and Depression Scale (HADS, theoretical range: 0-42, where a higher score indicates more general distress).	At screening
Symptom domains surveyed primarily to assess the feasibility of the measurement method: Body image distress.	Body Image Scale (BIS, theoretical range: 0-30, where a higher score indicates a higher level of body image distress).	Screening (within 6 months before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days).

Collaborators and Investigators

• Sponsor: Karolinska Institutet
• Investigators: Principal Investigator: Erland Axelsson, PhD, Karolinska Institutet

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2024
• Primary Completion (Actual): October 22, 2024
• Study Completion (Actual): October 22, 2024

Study Registration Dates

• First Submitted: September 6, 2023
• First Submitted That Met QC Criteria: September 13, 2023
• First Posted (Actual): September 21, 2023

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 13, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: psycho-oncology; randomized factorial trial; Internet-delivered cognitive behavior therapy
• Additional Relevant MeSH Terms: Behavioral Symptoms; Depression
• Other Study ID Numbers: 2023-04056-01 #1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data from this pilot study fall under Swedish and European Union data protection and privacy legislation and can therefore not be share in their entirety. Reasonable requests may be directed to the corresponding author, and will be considered on a case-by-case basis.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No